These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34239995)

  • 41. Reasons why not all Danish patients with muscle invasive bladder cancer receive neoadjuvant chemotherapy before radical cystectomy.
    Nielsen N; Wrist Lam G; Fabrin K; Holt P; Thind PO; Jensen JB
    Scand J Urol; 2019 Aug; 53(4):213-216. PubMed ID: 31174449
    [No Abstract]   [Full Text] [Related]  

  • 42. Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy.
    Bree KK; Hensley PJ; Westerman ME; Kokorovic A; Nogueras-Gonzalez GM; Dinney CP; Kamat AM; Navai N
    J Urol; 2021 Sep; 206(3):577-585. PubMed ID: 33872050
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association between precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and oncological outcomes in urothelial bladder cancer.
    Bazargani ST; Clifford TG; Djaladat H; Schuckman AK; Wayne K; Miranda G; Cai J; Sadeghi S; Dorff T; Quinn DI; Daneshmand S
    Urol Oncol; 2019 Jan; 37(1):1-11. PubMed ID: 30470611
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscle-invasive bladder cancer treated with cisplatin-based neoadjuvant chemotherapy and radical cystectomy: a single-centre experience.
    Boeri L; Soligo M; Frank I; Boorjian SA; Thompson RH; Tollefson M; Quevedo FJ; Cheville JC; Karnes RJ
    BJU Int; 2019 Jun; 123(6):1011-1019. PubMed ID: 30623554
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy.
    Lotan Y; de Jong JJ; Liu VYT; Bismar TA; Boorjian SA; Huang HC; Davicioni E; Mian OY; Wright JL; Necchi A; Dall'Era MA; Kaimakliotis HZ; Black PC; Gibb EA; Boormans JL
    J Urol; 2022 Mar; 207(3):541-550. PubMed ID: 34643090
    [TBL] [Abstract][Full Text] [Related]  

  • 46. KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer.
    Jütte H; Reike M; Wirtz RM; Kriegmair M; Erben P; Tully K; Weyerer V; Eckstein M; Hartmann A; Eidt S; Wezel F; Bolenz C; Tannapfel A; Noldus J; Roghmann F
    J Pers Med; 2021 May; 11(6):. PubMed ID: 34073233
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings.
    Rose TL; Deal AM; Basch E; Godley PA; Rathmell WK; Kim WY; Whang YE; Dunn MW; Wang A; Chen RC; Nielsen ME; Pruthi RS; Wallen EM; Woods ME; Smith AB; Milowsky MI
    Urol Oncol; 2015 Sep; 33(9):386.e1-6. PubMed ID: 26122712
    [TBL] [Abstract][Full Text] [Related]  

  • 48. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.
    Kitamura H; Tsukamoto T; Shibata T; Masumori N; Fujimoto H; Hirao Y; Fujimoto K; Kitamura Y; Tomita Y; Tobisu K; Niwakawa M; Naito S; Eto M; Kakehi Y;
    Ann Oncol; 2014 Jun; 25(6):1192-8. PubMed ID: 24669010
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Delays in radical cystectomy for muscle-invasive bladder cancer.
    Chu AT; Holt SK; Wright JL; Ramos JD; Grivas P; Yu EY; Gore JL
    Cancer; 2019 Jun; 125(12):2011-2017. PubMed ID: 30840335
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neoadjuvant therapy for muscle-invasive bladder cancer.
    Jain RK; Sonpavde G
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):603-614. PubMed ID: 32546025
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fewer tumour draining sentinel nodes in patients with progressing muscle invasive bladder cancer, after neoadjuvant chemotherapy and radical cystectomy.
    Alvaeus J; Rosenblatt R; Johansson M; Alamdari F; Jakubczyk T; Holmström B; Hemdan T; Huge Y; Aljabery F; Gabrielsson S; Riklund K; Winqvist O; Sherif A
    World J Urol; 2020 Sep; 38(9):2207-2213. PubMed ID: 31760442
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical predictors and survival outcome of patients receiving suboptimal neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: a single-center experience.
    Boeri L; Soligo M; Frank I; Boorjian SA; Thompson RH; Tollefson M; Tarrel R; Quevedo FJ; Cheville JC; Karnes RJ
    World J Urol; 2019 Nov; 37(11):2409-2418. PubMed ID: 30805684
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy.
    Culp SH; Dickstein RJ; Grossman HB; Pretzsch SM; Porten S; Daneshmand S; Cai J; Groshen S; Siefker-Radtke A; Millikan RE; Czerniak B; Navai N; Wszolek MF; Kamat AM; Dinney CP
    J Urol; 2014 Jan; 191(1):40-7. PubMed ID: 23911605
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer.
    Martini A; Jia R; Ferket BS; Waingankar N; Plimack ER; Crabb SJ; Harshman LC; Yu EY; Powles T; Rosenberg JE; Pal SK; Vaishampayan UN; Necchi A; Wiklund NP; Mehrazin R; Mazumdar M; Sfakianos JP; Galsky MD
    Cancer; 2019 Sep; 125(18):3155-3163. PubMed ID: 31150110
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Disease Management of Clinical Complete Responders to Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer: A Review of Literature.
    Wu J; Xie RY; Cao CZ; Shang BQ; Shi HZ; Shou JZ
    Front Oncol; 2022; 12():816444. PubMed ID: 35494010
    [TBL] [Abstract][Full Text] [Related]  

  • 57. History of Non-Muscle-Invasive Bladder Cancer May Have a Worse Prognostic Impact in cT2-4aN0M0 Bladder Cancer Patients Treated With Radical Cystectomy.
    Kayama E; Kikuchi E; Fukumoto K; Shirotake S; Miyazaki Y; Hakozaki K; Kaneko G; Yoshimine S; Tanaka N; Takahiro M; Kanai K; Oyama M; Nakajima Y; Hara S; Monma T; Oya M
    Clin Genitourin Cancer; 2018 Oct; 16(5):e969-e976. PubMed ID: 29778322
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predicting Response to Neoadjuvant Chemotherapy in Bladder Cancer.
    Motterle G; Andrews JR; Morlacco A; Karnes RJ
    Eur Urol Focus; 2020 Jul; 6(4):642-649. PubMed ID: 31708469
    [TBL] [Abstract][Full Text] [Related]  

  • 59. microRNA expression profiles as decision-making biomarkers in the management of bladder cancer.
    Amir S; Mabjeesh NJ
    Histol Histopathol; 2017 Feb; 32(2):107-119. PubMed ID: 27586262
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High aurora kinase expression identifies patients with muscle-invasive bladder cancer who have poor survival after neoadjuvant chemotherapy.
    Burgess EF; Livasy C; Trufan S; Hartman A; Guerreri R; Naso C; Clark PE; Grigg C; Symanowski J; Raghavan D
    Urol Oncol; 2019 Dec; 37(12):900-906. PubMed ID: 31597600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.